NYSE:ENZ', 'Enzo Biochem Inc.', 'http://kldaily.com/kl-logo.png');

A Reversal for Enzo Biochem Incorporated (NYSE:ENZ) Is Not Near. The Stock Has Rise in Shorts

December 11, 2017 - By Adrian Erickson

 A Reversal for Enzo Biochem Incorporated (NYSE:ENZ) Is Not Near. The Stock Has Rise in Shorts

Investors sentiment increased to 1.59 in 2017 Q2. Its up 0.30, from 1.29 in 2017Q1. It is positive, as 12 investors sold Enzo Biochem, Inc. shares while 27 reduced holdings. 28 funds opened positions while 34 raised stakes. 25.22 million shares or 2.12% more from 24.70 million shares in 2017Q1 were reported.
Brookstone Mngmt owns 20,000 shares for 0.02% of their portfolio. Deutsche Commercial Bank Ag reported 72,347 shares or 0% of all its holdings. First Light Asset Mngmt Llc holds 403,082 shares. Bnp Paribas Arbitrage Sa reported 0% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ). American Century invested in 0% or 47,329 shares. Moreover, Two Sigma Securities Llc has 0.02% invested in Enzo Biochem, Inc. (NYSE:ENZ). Eam Lc owns 159,930 shares for 0.29% of their portfolio. Renaissance Lc reported 0.03% in Enzo Biochem, Inc. (NYSE:ENZ). Citigroup invested 0% in Enzo Biochem, Inc. (NYSE:ENZ). Vanguard Group Inc reported 1.75 million shares or 0% of all its holdings. Kopp Investment Advsrs Ltd Liability Company reported 199,132 shares. Prudential Incorporated holds 0% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ) for 90,550 shares. Barclays Public Lc holds 0% in Enzo Biochem, Inc. (NYSE:ENZ) or 32,834 shares. Bogle Invest Mgmt Ltd Partnership De owns 107,576 shares. 119,006 were reported by Federated Investors Pa.

The stock of Enzo Biochem Incorporated (NYSE:ENZ) registered an increase of 1.9% in short interest. ENZ’s total short interest was 842,700 shares in December as published by FINRA. Its up 1.9% from 827,000 shares, reported previously. With 262,000 shares average volume, it will take short sellers 3 days to cover their ENZ’s short positions. The short interest to Enzo Biochem Incorporated’s float is 2%.

The stock increased 0.11% or $0.01 during the last trading session, reaching $8.8. About 27,843 shares traded. Enzo Biochem, Inc. (NYSE:ENZ) has risen 44.32% since December 11, 2016 and is uptrending. It has outperformed by 27.62% the S&P500.

Enzo Biochem, Inc., an integrated diagnostic bioscience company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company has market cap of $412.95 million. The firm operates in three divisions: Clinical Labs, Life Sciences, and Therapeutics. It currently has negative earnings. The Clinical Labs segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, and search for an otherwise undiagnosed condition.

More notable recent Enzo Biochem, Inc. (NYSE:ENZ) news were published by: Seekingalpha.com which released: “Enzo Biochem (ENZ) on Q3 2017 Results – Earnings Call Transcript” on June 09, 2017, also Seekingalpha.com with their article: “Enzo Biochem Rounds The Corner” published on July 10, 2017, Businesswire.com published: “Enzo Biochem Announces NYS Department of Health’s Approval of a New Women’s …” on October 23, 2017. More interesting news about Enzo Biochem, Inc. (NYSE:ENZ) were released by: Seekingalpha.com and their article: “Enzo Biochem’s (ENZ) on Q2 2017 Results – Earnings Call Transcript” published on March 14, 2017 as well as Businesswire.com‘s news article titled: “Enzo Biochem Schedules Teleconference to Discuss First Quarter 2018 Results …” with publication date: December 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.